Asia-Pacific Monoclonal Antibodies Market Growth, Size, Share, Industry Report and Forecast 2021-2027
Asia-Pacific monoclonal antibodies market is estimated to grow at a CAGR of 8.9% during the forecast period. Rising cancer incidences is the major factor in accelerating market growth. As per the World Health Organization (WHO), there were 4.3 million new cancer incidences reported in the country. Of these, lung (18.1%), colorectum (12.2%), stomach (10.6%), liver (9.2%), breast (8.6%), and other cancers (41.4%) of all new cancer cases in the country. Rising awareness regarding early detection of cancer has been witnessed in the country, which is supporting the increasing demand for novel cancer therapies. Monoclonal antibodies are laboratory-engineered molecules designed to attack particular features that are found on cancer cells. These antibodies are designed to discover specific proteins on cancer cells that are associated with the growth of those cells. These therapies may also be utilized to deliver radiation or chemotherapy directly to cancer cells. Monoclonal antibody drugs can function in several ways, including blocking cell growth and immune system inhibitors, flagging cancer cells, delivering chemotherapy and radiation treatment, directly attacking cancer cells, and others.
To Request a Sample of our Report on Asia-Pacific
Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/asia-pacific-monoclonal-antibodies-market
Scope of the Asia-Pacific Monoclonal Antibodies Market
Market Coverage
·
Market number available for 2019-2026
·
Base year- 2019
·
Forecast period- 2020-2026
·
Segment Covered- By Source and Application
·
Regions Covered- China, India, Japan, and Rest of
Asia-Pacific
·
Competitive Landscape- Biocon Ltd., Amgen Inc., F.
Hoffman La-Roche AG, Pfizer Inc., and Mylan N.V.
Recent Strategic Initiatives in the Asia-Pacific Monoclonal Antibodies
Market
·
In July 2020, Cadila Pharmaceuticals Ltd. declared the
introduction of biosimilar Rituximab in India. It is indicated for the
treatment of rheumatoid arthritis and blood cancer launched within the brand
name Ritucad. It is used to treat Non-Hodgkin’s lymphoma (a type of
blood-related cancer). According to the company, over 28,000 new cases of
Lymphoma are reported each year in India. This launch will increase the
accessibility of cancer treatment in the country.
·
In October 2019, Amgen declared collaboration with
BeiGene that will further widen Amgen's plans to enhance its oncology presence
in China. Under the agreement, BeiGene will commercialize BLINCYTO
(blinatumomab), XGEVA (denosumab), and KYPROLIS (carfilzomib) in China.
Additionally, this acquisition will also support Amgen for the
commercialization of its non-oncology product portfolio in China.
Key questions addressed by the report
·
What is the market growth rate?
·
Which segment dominates the market in the base year?
·
Which segment will project the fastest growth in the
market?
·
How COVID-19 impacted the market?
·
Recovery Timeline
·
Deviation from the pre-COVID forecast
·
Most affected segment
·
Who is the leader in the market?
·
How players are addressing challenges to sustain growth?
·
Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A
full Report of Asia-Pacific Monoclonal Antibodies Market is Available
at: https://www.omrglobal.com/industry-reports/asia-pacific-monoclonal-antibodies-market
Asia-Pacific Monoclonal
Antibodies Market Segmentation
By Source
·
Murine
·
Chimeric
·
Human
·
Humanized
By Application
·
Cancer
·
Infectious Diseases
·
Auto-Immune Diseases
·
Inflammatory Diseases
·
Others
Asia-Pacific Monoclonal Antibodies Market– Segment by Country
·
China
·
Japan
·
India
Rest of Asia-Pacific
Company Profiles
·
Amgen Inc.
·
Anhui Anke Biotechnology (Group) Co., Ltd.
·
Biocon Ltd.
·
Chugai Pharmaceutical Co., Ltd.
·
Daiichi Sankyo Company, Ltd.
·
Dr. Reddy's Laboratories, Inc.
·
GenorBioPharma Co., Ltd.
·
Lupin Ltd.
·
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
·
Takeda Pharmaceutical Co., Ltd.
·
Zhejiang Hisun Pharmaceutical Co., Ltd.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data, Request for
Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-monoclonal-antibodies-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment